Sagar Lonial

Summary

Affiliation: Emory University
Country: USA

Publications

  1. ncbi Treatment of relapsed and refractory myeloma
    Jonathan Kaufman
    Winship Cancer Institute, Emory University, 1365 Clifton Road, Building C, Room 4004, Atlanta, GA 30322, USA
    Curr Hematol Malig Rep 4:99-107. 2009
  2. ncbi Mobilization of hematopoietic progenitors from normal donors using the combination of granulocyte-macrophage colony-stimulating factor and granulocyte colony-stimulating factor results in fewer plasmacytoid dendritic cells in the graft and enhanced donor
    Sagar Lonial
    Department of Hematology and Medical Oncology, Winship Cancer Institute of Emory University, Atlanta, GA 30322, USA
    Biol Blood Marrow Transplant 19:460-7. 2013
  3. ncbi Induction therapy for newly diagnosed multiple myeloma
    Sagar Lonial
    Department of Hematology and Medical Oncology, Winship Cancer Institute of Emory University, Atlanta, Georgia, USA
    J Natl Compr Canc Netw 11:19-28. 2013
  4. ncbi Elotuzumab in combination with lenalidomide and low-dose dexamethasone in relapsed or refractory multiple myeloma
    Sagar Lonial
    Winship Cancer Institute, Emory University, Atlanta, GA, USA
    J Clin Oncol 30:1953-9. 2012
  5. ncbi Risk factors and kinetics of thrombocytopenia associated with bortezomib for relapsed, refractory multiple myeloma
    Sagar Lonial
    Winship Cancer Institute, Emory University, Atlanta, GA, USA
    Blood 106:3777-84. 2005
  6. ncbi Treatment options for relapsed and refractory multiple myeloma
    Sagar Lonial
    Department of Hematology and Medical Oncology, Winship Cancer Institute, Emory University School of Medicine, Atlanta, Georgia, USA
    Clin Cancer Res 17:1264-77. 2011
  7. ncbi The addition of rituximab to anthracycline-based chemotherapy significantly improves outcome in 'Western' patients with intravascular large B-cell lymphoma
    Andres J M Ferreri
    Unit of Lymphoid Malignancies and Medical Oncology Unit, Department of Oncology, San Raffaele H Scientific Institute, Milano, Italy
    Br J Haematol 143:253-7. 2008
  8. ncbi Regulation of alloimmune responses by dendritic cell subsets
    Sagar Lonial
    Winship Cancer Institute, Emory University School of Medicine, Atlanta, GA 30322, USA
    Exp Hematol 36:1309-17. 2008
  9. ncbi Multiple myeloma: novel approaches for relapsed disease
    Sagar Lonial
    Winship Cancer Institute, Emory University School of Medicine, 1365 Clifton Road, Atlanta, GA 30322, USA
    Clin Lymphoma Myeloma 8:S18-23. 2007
  10. ncbi Results of a clinical phase I dose-escalation study of cytarabine in combination with fixed-dose vinorelbine, paclitaxel, etoposide and cisplatin for the treatment of relapsed/refractory lymphoma
    Sagar Lonial
    Winship Cancer Institute, Emory University School of Medicine, Atlanta, Georgia, USA
    Leuk Lymphoma 47:2155-62. 2006

Collaborators

Detail Information

Publications84

  1. ncbi Treatment of relapsed and refractory myeloma
    Jonathan Kaufman
    Winship Cancer Institute, Emory University, 1365 Clifton Road, Building C, Room 4004, Atlanta, GA 30322, USA
    Curr Hematol Malig Rep 4:99-107. 2009
    ....
  2. ncbi Mobilization of hematopoietic progenitors from normal donors using the combination of granulocyte-macrophage colony-stimulating factor and granulocyte colony-stimulating factor results in fewer plasmacytoid dendritic cells in the graft and enhanced donor
    Sagar Lonial
    Department of Hematology and Medical Oncology, Winship Cancer Institute of Emory University, Atlanta, GA 30322, USA
    Biol Blood Marrow Transplant 19:460-7. 2013
    ..The use of GM+G-CSF modulates immune function and recovery after allogeneic transplantation and should be explored in larger studies powered to evaluate clinical outcomes...
  3. ncbi Induction therapy for newly diagnosed multiple myeloma
    Sagar Lonial
    Department of Hematology and Medical Oncology, Winship Cancer Institute of Emory University, Atlanta, Georgia, USA
    J Natl Compr Canc Netw 11:19-28. 2013
    ....
  4. ncbi Elotuzumab in combination with lenalidomide and low-dose dexamethasone in relapsed or refractory multiple myeloma
    Sagar Lonial
    Winship Cancer Institute, Emory University, Atlanta, GA, USA
    J Clin Oncol 30:1953-9. 2012
    ..This phase I study evaluated elotuzumab, lenalidomide, and dexamethasone in patients with relapsed or refractory multiple myeloma (MM)...
  5. ncbi Risk factors and kinetics of thrombocytopenia associated with bortezomib for relapsed, refractory multiple myeloma
    Sagar Lonial
    Winship Cancer Institute, Emory University, Atlanta, GA, USA
    Blood 106:3777-84. 2005
    ..The exact mechanism underlying bortezomib-induced thrombocytopenia remains unknown but it is unlikely to be related to marrow injury or decreased thrombopoietin production...
  6. ncbi Treatment options for relapsed and refractory multiple myeloma
    Sagar Lonial
    Department of Hematology and Medical Oncology, Winship Cancer Institute, Emory University School of Medicine, Atlanta, Georgia, USA
    Clin Cancer Res 17:1264-77. 2011
    ..Together each of these treatment approaches are being tested in phase I, II, and III clinical trials, with the goal of prolonged duration of remission and, ultimately, improved overall survival...
  7. ncbi The addition of rituximab to anthracycline-based chemotherapy significantly improves outcome in 'Western' patients with intravascular large B-cell lymphoma
    Andres J M Ferreri
    Unit of Lymphoid Malignancies and Medical Oncology Unit, Department of Oncology, San Raffaele H Scientific Institute, Milano, Italy
    Br J Haematol 143:253-7. 2008
    ..50%; P = 0.04), event-free survival (3-year: 89% vs. 35%; P = 0.003) and overall survival (3-year: 89% vs. 38%; P = 0.01). In conclusion, rituximab may substantially change the dismal prognosis of IVL...
  8. ncbi Regulation of alloimmune responses by dendritic cell subsets
    Sagar Lonial
    Winship Cancer Institute, Emory University School of Medicine, Atlanta, GA 30322, USA
    Exp Hematol 36:1309-17. 2008
    ..In order to better understand the effect of DC subsets on regulation of immunity, we tested the effect of DC subsets on T cells in a model of indirect antigen presentation to mimic presentation of host-type alloantigen by donor-type DC...
  9. ncbi Multiple myeloma: novel approaches for relapsed disease
    Sagar Lonial
    Winship Cancer Institute, Emory University School of Medicine, 1365 Clifton Road, Atlanta, GA 30322, USA
    Clin Lymphoma Myeloma 8:S18-23. 2007
    ..This review summarizes emerging data on novel agents, alkylating agents, and their combinations in the setting of newly diagnosed and relapsed MM...
  10. ncbi Results of a clinical phase I dose-escalation study of cytarabine in combination with fixed-dose vinorelbine, paclitaxel, etoposide and cisplatin for the treatment of relapsed/refractory lymphoma
    Sagar Lonial
    Winship Cancer Institute, Emory University School of Medicine, Atlanta, Georgia, USA
    Leuk Lymphoma 47:2155-62. 2006
    ....
  11. ncbi Farnesyl transferase inhibitors, autophagy, and proteasome inhibition: synergy for all the right reasons
    Sagar Lonial
    Department of and Medical Oncology, Winship Cancer Institute, Emory University School of Medicine Atlanta, GA, USA
    Autophagy 7:448-9. 2011
    ....
  12. ncbi Characterisation of haematological profiles and low risk of thromboembolic events with bortezomib in patients with relapsed multiple myeloma
    Sagar Lonial
    Emory University, Atlanta, GA 30322, USA
    Br J Haematol 143:222-9. 2008
    ..Preliminary data suggest bortezomib may reduce the thrombogenic potential of combination regimens via inhibition of platelet function or other mechanism-specific effects on coagulation...
  13. ncbi A randomized trial comparing the combination of granulocyte-macrophage colony-stimulating factor plus granulocyte colony-stimulating factor versus granulocyte colony-stimulating factor for mobilization of dendritic cell subsets in hematopoietic progenitor
    Sagar Lonial
    Winship Cancer Institute, Emory University School of Medicine, 1365 Clifton Road, Atlanta, GA 30322, USA
    Biol Blood Marrow Transplant 10:848-57. 2004
    ....
  14. ncbi A phase I/II trial combining high-dose melphalan and autologous transplant with bortezomib for multiple myeloma: a dose- and schedule-finding study
    Sagar Lonial
    Department of Hematology and Medical Oncology, Winship Cancer Institute, Emory University School of Medicine, Atlanta, Georgia 30322, USA
    Clin Cancer Res 16:5079-86. 2010
    ..We did a randomized phase I/II trial designed to evaluate the safety and efficacy of combining the proteasome inhibitor bortezomib with high-dose melphalan as the conditioning for high-dose therapy and autologous transplant for myeloma...
  15. ncbi Presentation and risk stratification--improving prognosis for patients with multiple myeloma
    Sagar Lonial
    Winship Cancer Institute, Emory University School of Medicine, Atlanta, GA 30322, USA
    Cancer Treat Rev 36:S12-7. 2010
    ..Large, prospective randomised studies are needed to confirm these early pilot studies...
  16. ncbi Signal transduction and myeloma: new targets, new hope
    Sagar Lonial
    Winship Cancer Institute Emory University School of Medicine Atlanta, Georgia USA
    Cancer Biol Ther 2:310-9. 2003
    ..The final section will assess the potential for new targeted approaches to treatment for mechanisms which have yet to be fully explored, and for agents which are in early phase I development..
  17. ncbi Relapsed multiple myeloma
    Sagar Lonial
    Department of Hematology and Medical Oncology, Winship Cancer Institute, Emory University School of Medicine, Atlanta, GA 30322, USA
    Hematology Am Soc Hematol Educ Program 2010:303-9. 2010
    ..Further clinical and translational testing are critical to better understanding how best to combine these new agents, as well as identifying patient populations that may best benefit from treatment with these developing new agents...
  18. ncbi Emerging combination treatment strategies containing novel agents in newly diagnosed multiple myeloma
    Sagar Lonial
    Winship Cancer Institute, Emory University, Atlanta, GA 30322, USA
    Br J Haematol 145:681-708. 2009
    ..We also review data on response and outcomes in patients with poor prognostic characteristics that indicate that the adverse impact typically seen with these factors may be overcome using novel-agent therapy...
  19. ncbi Practical considerations for multiple myeloma: an overview of recent data and current options
    Sagar Lonial
    Winship Cancer Institute, Emory University School of Medicine, Atlanta, GA, USA
    Clin Lymphoma Myeloma 8:S144-8. 2008
    ..This review will summarize some of the most promising combinations of novel agents in the induction therapy setting and briefly discuss the effect of additional emerging novel agents in the relapsed disease setting...
  20. ncbi Future directions in immunomodulatory therapy
    Sagar Lonial
    Emory University School of Medicine, Atlanta, GA, USA
    Med Oncol 27:S62-6. 2010
    ..Further clinical development of immunomodulatory agents should continue to be based on preclinical rationale, which has resulted in a number of promising and clinically active combinations...
  21. ncbi The proteasome inhibitor PS-341 (bortezomib) up-regulates DR5 expression leading to induction of apoptosis and enhancement of TRAIL-induced apoptosis despite up-regulation of c-FLIP and survivin expression in human NSCLC cells
    Xiangguo Liu
    Department of Hematology and Oncology, Winship Cancer Institute, Emory University School of Medicine, Atlanta, Georgia 30322, USA
    Cancer Res 67:4981-8. 2007
    ..Thus, the present study highlights the important role of DR5 up-regulation in PS-341-induced apoptosis and enhancement of TRAIL-induced apoptosis in human NSCLC cells...
  22. ncbi Perifosine synergistically enhances TRAIL-induced myeloma cell apoptosis via up-regulation of death receptors
    Ebenezer David
    Department of Hematology and Oncology, Winship Cancer Institute, Emory University School of Medicine, Atlanta, Georgia, USA
    Clin Cancer Res 14:5090-8. 2008
    ..The aim of this study is to investigate the efficacy of a novel Akt inhibitor, perifosine, in combination with tumor necrosis factor-related apoptosis-inducing ligand (TRAIL) in human myeloma cells and primary patient samples...
  23. ncbi Bortezomib, thalidomide, and dexamethasone as induction therapy for patients with symptomatic multiple myeloma: a retrospective study
    Jonathan L Kaufman
    Winship Cancer Institute, Emory University, Atlanta, Georgia 30322, USA
    Cancer 116:3143-51. 2010
    ..This single-center retrospective study determined the efficacy of bortezomib, thalidomide, and dexamethasone (BTD) as induction for patients with multiple myeloma (MM) who were eligible for autologous stem cell transplantation (ASCT)...
  24. ncbi Effectiveness and cost analysis of "just-in-time" salvage plerixafor administration in autologous transplant patients with poor stem cell mobilization kinetics
    Jie Li
    Winship Cancer Institute, Department of Hematology Oncology, Emory University School of Medicine, Atlanta, Georgia 30322, USA
    Transfusion 51:2175-82. 2011
    ..Plerixafor is a recently Food and Drug Administration (FDA)-approved CXCR4 antagonist, which is combined with granulocyte-colony-stimulating factor (G-CSF) to facilitate stem cell mobilization of lymphoma and myeloma patients...
  25. ncbi A phase 1 dose escalation study of bortezomib combined with rituximab, cyclophosphamide, doxorubicin, modified vincristine, and prednisone for untreated follicular lymphoma and other low-grade B-cell lymphomas
    Rajni Sinha
    Department of Hematology and Medical Oncology, Winship Cancer Institute, Emory University School of Medicine, Atlanta, GA 30322, USA
    Cancer 118:3538-48. 2012
    ..A phase 1 study of bortezomib combined with rituximab, cyclophosphamide, doxorubicin, modified vincristine, and prednisone (R-CHOP) was conducted in patients with untreated follicular lymphoma (FL) and other indolent NHLs...
  26. ncbi FGFR3 activates RSK2 to mediate hematopoietic transformation through tyrosine phosphorylation of RSK2 and activation of the MEK/ERK pathway
    Sumin Kang
    Winship Cancer Institute, Emory University School of Medicine, Atlanta, GA 30322, USA
    Cancer Cell 12:201-14. 2007
    ..Our findings suggest that FGFR3 mediates hematopoietic transformation by activating RSK2 in a two-step fashion, promoting both the ERK-RSK2 interaction and subsequent phosphorylation of RSK2 by ERK...
  27. ncbi Epidermal growth factor stimulates RSK2 activation through activation of the MEK/ERK pathway and src-dependent tyrosine phosphorylation of RSK2 at Tyr-529
    Sumin Kang
    Winship Cancer Institute, Emory University School of Medicine, Atlanta, Georgia 30322, USA
    J Biol Chem 283:4652-7. 2008
    ..Together, our findings suggest that Src-dependent phosphorylation at Tyr-529 facilitates inactive ERK binding to RSK2, which might be a general requirement for RSK2 activation by EGF through the MEK/ERK pathway...
  28. ncbi Tipifarnib sensitizes cells to proteasome inhibition by blocking degradation of bortezomib-induced aggresomes
    Ebenezer David
    Winship Cancer Institute of Emory University, Department of Hematology and Medical Oncology, School of Medicine, Atlanta, GA, USA
    Blood 116:5285-8. 2010
    ..Together, these data demonstrate that tipifarnib synergizes with bortezomib by inducing protein accumulation as a result of the uncoupling of the aggresome and autophagy pathways...
  29. ncbi Tyrosine phosphorylation of mitochondrial pyruvate dehydrogenase kinase 1 is important for cancer metabolism
    Taro Hitosugi
    Department of Hematology and Medical Oncology, Winship Cancer Institute of Emory, Emory University School of Medicine, Atlanta, GA 30322, USA
    Mol Cell 44:864-77. 2011
    ..Together, tyrosine phosphorylation activates PDHK1 to promote the Warburg effect and tumor growth...
  30. ncbi Facilitating T-cell immune reconstitution after haploidentical transplantation in adults
    Edmund K Waller
    Division of Hematology Oncology, Winship Cancer Institute, Emory University, Atlanta, GA 30322, USA
    Blood Cells Mol Dis 33:233-7. 2004
    ..A planned clinical phase 1 trial of adoptive therapy utilizing ex vivo psoralen-treated donor T-cells in recipients of T-cell-depleted haploidentical HPCT is presented...
  31. ncbi A randomized clinical trial comparing granulocyte-colony-stimulating factor administration sites for mobilization of peripheral blood stem cells for patients with hematologic malignancies undergoing autologous stem cell transplantation
    Heather Renfroe
    Winship Cancer Institute, Emory University School of Medicine, Atlanta, GA 30322, USA
    Transfusion 51:1779-83. 2011
    ....
  32. ncbi Optimizing the timing of chemotherapy for mobilizing autologous blood hematopoietic progenitor cells
    Michelle L Hicks
    Winship Cancer Institute, Emory University School of Medicine, Atlanta, Georgia, USA
    Transfusion 47:629-35. 2007
    ..Postchemotherapy mobilization results were reviewed in patients undergoing apheresis before planned autologous hematopoietic progenitor cell (HPC) transplantation to improve the timing of collection procedures...
  33. ncbi Novel treatment approaches for patients with multiple myeloma
    Rajni Sinha
    Winship Cancer Institute, Emory University School of Medicine, Atlanta, GA 30322, USA
    Clin Lymphoma Myeloma 6:281-8. 2006
    ..Clinical trial development based on preclinically designed rational combinations and targets have the potential to rapidly translate these findings into meaningful clinical responses...
  34. ncbi Fibroblast growth factor receptor 3 associates with and tyrosine phosphorylates p90 RSK2, leading to RSK2 activation that mediates hematopoietic transformation
    Sumin Kang
    Winship Cancer Institute, Emory University School of Medicine, Atlanta, GA 30322, USA
    Mol Cell Biol 29:2105-17. 2009
    ..Our current and previous findings represent a paradigm for tyrosine phosphorylation-dependent regulation of serine-threonine kinases...
  35. ncbi The alkylphospholipid perifosine induces apoptosis of human lung cancer cells requiring inhibition of Akt and activation of the extrinsic apoptotic pathway
    Heath A Elrod
    Winship Cancer Institute, Emory University School of Medicine, 1365 C Clifton Road Northeast, C3088, Atlanta, GA 30322, USA
    Mol Cancer Ther 6:2029-38. 2007
    ..Moreover, perifosine cooperates with TRAIL to enhance the induction of apoptosis in human NSCLC cells, thus warranting future in vivo and clinical evaluation of perifosine in combination with TRAIL in the treatment of NSCLC...
  36. ncbi Reconstructing immunity after allogeneic transplantation
    Cynthia R Giver
    Blood Cell Therapy Laboratory, Winship Cancer Institute, Emory University, 1365C Clifton Road, Rm. 4002, Atlanta, GA 30322, USA
    Immunol Res 29:269-82. 2004
    ..A model that differentiates GVT from GVHD based on interaction of T-cell subsets with DC subsets is proposed...
  37. ncbi Pharmacokinetics and pharmacodynamics of anti-thymocyte globulin in recipients of partially HLA-matched blood hematopoietic progenitor cell transplantation
    Edmund K Waller
    Winship Cancer Institute, Emory University, 1701 Uppergate Dr, Atlanta, GA 30322, USA
    Biol Blood Marrow Transplant 9:460-71. 2003
    ....
  38. ncbi Tyrosine phosphorylation inhibits PKM2 to promote the Warburg effect and tumor growth
    Taro Hitosugi
    Winship Cancer Institute, Emory University School of Medicine, Atlanta, GA 30322, USA
    Sci Signal 2:ra73. 2009
    ..Our findings suggest that tyrosine phosphorylation regulates PKM2 to provide a metabolic advantage to tumor cells, thereby promoting tumor growth...
  39. ncbi Early clearance of peripheral blood blasts predicts response to induction chemotherapy in acute myeloid leukemia
    Martha Arellano
    Departments of Hematology and Medical Oncology, Winship Cancer Institute of Emory University, Atlanta, GA 30322, USA
    Cancer 118:5278-82. 2012
    ..Early marrow blast clearance 14 days after induction chemotherapy is an independent prognostic indicator of outcomes in acute myeloid leukemia (AML)...
  40. ncbi Tyrosine phosphorylation of lactate dehydrogenase A is important for NADH/NAD(+) redox homeostasis in cancer cells
    Jun Fan
    Department of Hematology and Medical Oncology, Winship Cancer Institute of Emory, Emory University School of Medicine, Atlanta, GA 30322, USA
    Mol Cell Biol 31:4938-50. 2011
    ....
  41. ncbi Maintenance therapy with thalidomide improves overall survival after autologous hematopoietic progenitor cell transplantation for multiple myeloma
    Brett T Brinker
    Division of Hematology and Oncology, Winship Cancer Institute, Emory University School of Medicine, Atlanta, Georgia 30322, USA
    Cancer 106:2171-80. 2006
    ..Further prospective trials are underway to confirm the benefit of thalidomide in the posttransplantation setting...
  42. ncbi A prospective clinical trial evaluating the safety and efficacy of the combination of rituximab and plerixafor as a mobilization regimen for patients with lymphoma
    Jonathan L Kaufman
    Winship Cancer Institute, Emory University School of Medicine, Atlanta, GA 30322, USA
    Transfusion 53:76-84. 2013
    ..Previous reports suggested that rituximab may impair stem cell collection and posttransplant engraftment in lymphoma patients undergoing autologous hematopoietic progenitor cell transplantation...
  43. ncbi Ex vivo fludarabine exposure inhibits graft-versus-host activity of allogeneic T cells while preserving graft-versus-leukemia effects
    Cynthia R Giver
    Hematology/Oncology Department, Winship Cancer Institute, Emory University, 1639 Pierce Drive, Atlanta, GA 30322, USA
    Biol Blood Marrow Transplant 9:616-32. 2003
    ..Thus, F-DLI represents a novel method of immune modulation that may be useful to enhance immune reconstitution among allograft recipients with reduced risk of GVHD while retaining beneficial GVL effects...
  44. ncbi Perifosine inhibits mammalian target of rapamycin signaling through facilitating degradation of major components in the mTOR axis and induces autophagy
    Lei Fu
    Department of Hematology, Winship Cancer Institute, Emory University School of Medicine, Atlanta, Georgia 30322, USA
    Cancer Res 69:8967-76. 2009
    ....
  45. ncbi The importance of complete response in outcomes in myeloma
    Ajay Nooka
    Winship Cancer Institute, Emory University, Atlanta, GA, USA
    Cancer J 15:465-72. 2009
    ....
  46. ncbi Proteasome inhibitor PS-341 (bortezomib) induces calpain-dependent IkappaB(alpha) degradation
    Chunyang Li
    Department of Hematology and Medical Oncology, Emory University School of Medicine and Winship Cancer Institute, Atlanta, Georgia 30322, USA
    J Biol Chem 285:16096-104. 2010
    ..Collectively, these unexpected findings suggest not only a novel paradigm regarding the relationship between proteasome inhibition and NF-kappaB activity but also a strategy to enhance the anticancer efficacy of PS-341...
  47. ncbi Improving induction therapy in multiple myeloma
    Ajay Nooka
    Emory University, Building C, Room 4004, 1365 Clifton Road, Atlanta, GA 30322, USA
    Curr Hematol Malig Rep 5:119-28. 2010
    ..Many challenges remain however, such as achieving greater depth of responses with molecular remissions and more effective use of risk stratification in induction therapy. These are still to be explored...
  48. ncbi Multiple myeloma: the role of transplant and novel treatment strategies
    Jonathan Kaufman
    Winship Cancer Institute, Emory University School of Medicine, Atlanta, GA 30322, USA
    Semin Oncol 31:99-105. 2004
    ..This review will discuss recent improvements in therapies for myeloma focusing on transplantation and novel targeted therapies...
  49. ncbi Receiver operating characteristic curve analysis of circulating blood dendritic cell precursors and T cells predicts response to extracorporeal photopheresis in patients with chronic graft-versus-host disease
    Mojtaba Akhtari
    Department of Hematology and Medical Oncology, Winship Cancer Institute, Atlanta, Georgia 30322, USA
    Transfusion 50:2424-31. 2010
    ..This hypothesis was tested by correlating numbers of DC precursors and T cells in the blood before and during ECP therapy with response of cGVHD...
  50. ncbi Phosphoglycerate mutase 1 coordinates glycolysis and biosynthesis to promote tumor growth
    Taro Hitosugi
    Department of Hematology and Medical Oncology, Winship Cancer Institute, Emory University School of Medicine, Atlanta, GA 30322, USA
    Cancer Cell 22:585-600. 2012
    ....
  51. ncbi The combination of the farnesyl transferase inhibitor lonafarnib and the proteasome inhibitor bortezomib induces synergistic apoptosis in human myeloma cells that is associated with down-regulation of p-AKT
    Ebenezer David
    Winship Cancer Institute, Emory University, 1365 Clifton Rd, Building C, Rm 4004, Atlanta, GA 30322, USA
    Blood 106:4322-9. 2005
    ..The combination of a proteasome inhibitor and farnesyl transferase inhibitor demonstrates synergistic myeloma-cell death and warrants further preclinical and clinical studies...
  52. ncbi Multiple myeloma presenting with advanced renal failure: a case report and new treatment options
    S Pierson Gladney
    Atlanta Hematology and Onclogy Associates, PC, GA, USA
    Clin Lymphoma Myeloma 8:52-4. 2008
    ..We review the data on treatment approaches for patients with renal failure and focus on the use of aggressive induction therapy with novel therapeutics...
  53. ncbi Tyr26 phosphorylation of PGAM1 provides a metabolic advantage to tumours by stabilizing the active conformation
    Taro Hitosugi
    1 Department of Haematology and Medical Oncology, Winship Cancer Institute of Emory, Emory University School of Medicine, Atlanta, Georgia 30322, USA 2
    Nat Commun 4:1790. 2013
    ....
  54. ncbi Proteasome inhibition: novel therapy for multiple myeloma
    Jonathan L Kaufman
    Winship Cancer Institute, Emory University School of Medicine, Atlanta, GA, USA
    Onkologie 29:162-8. 2006
    ..The success of proteasome inhibition in the treatment of myeloma is a model for effective translation of preclinical research into tangible clinical benefits for patients with cancer...
  55. ncbi Breakthroughs in the management of multiple myeloma
    Leonard T Heffner
    Winship Cancer Institute, Emory University School of Medicine, Atlanta, Georgia 30322, USA
    Drugs 63:1621-36. 2003
    ..Unfortunately, a cure for myeloma remains elusive but the continuing advances in management may significantly prolong survival in affected patients...
  56. ncbi Bone marrow mobilization with granulocyte macrophage colony-stimulating factor improves endothelial dysfunction and exercise capacity in patients with peripheral arterial disease
    Veerappan Subramaniyam
    Division of Cardiology, Emory University School of Medicine, 1364 Clifton Rd, Atlanta, GA 30322, USA
    Am Heart J 158:53-60.e1. 2009
    ....
  57. ncbi Maintenance therapy in lymphoma
    Ronald Mihelic
    Winship Cancer Institute, Emory University School of Medicine, Atlanta, GA 30322, USA
    Clin Lymphoma Myeloma 7:507-13. 2007
    ..Further studies are needed to characterize the benefits of other agents in maintenance therapy and other strategies for maintaining remissions for patients with NHL...
  58. ncbi The NEDD8-activating enzyme inhibitor, MLN4924, cooperates with TRAIL to augment apoptosis through facilitating c-FLIP degradation in head and neck cancer cells
    Liqun Zhao
    Department of Hematology and Medical Oncology, Emory University School of Medicine and Winship Cancer Institute, 1365 C Clifton Road NE, C3088, Atlanta, GA 30322, USA
    Mol Cancer Ther 10:2415-25. 2011
    ..Because knockdown of NEDD8 failed to activate JNK signaling and downregulate c-FLIP, it is likely that MLN4924 reduces c-FLIP levels and enhances TRAIL-induced apoptosis independent of NEDD8 inhibition...
  59. ncbi The farnesyltransferase inhibitor R115777 up-regulates the expression of death receptor 5 and enhances TRAIL-induced apoptosis in human lung cancer cells
    Yuanzheng Qiu
    Department of Hematology and Oncology, Winship Cancer Institute, Emory University School of Medicine, Atlanta, Georgia 30322, USA
    Cancer Res 67:4973-80. 2007
    ..Thus, our findings show the efficacy of R115777 in human lung cancer cells and suggest that R115777 may be used clinically in combination with TRAIL for treatment of human lung cancer...
  60. ncbi Complete remission of multiple myeloma
    Sagar Lonial
    B-cell Malignancy Program, Winship Cancer Institute, Emory University, Atlanta, GA 30322, USA
    Clin Adv Hematol Oncol 5:671-2, 675. 2007
  61. ncbi Sequential or combination therapy for multiple myeloma
    Ajay Nooka
    Department of Hematology and Medical Oncology, Winship Cancer Institute, Emory University School of Medicine, Atlanta, GA, USA
    Expert Rev Hematol 5:533-45. 2012
    ..However, with the use of more active novel agents with favorable toxicity profiles such as bortezomib, thalidomide and lenalidomide, re-evaluation of this question is necessary...
  62. ncbi Hepatitis C reactivation in patients who have diffuse large B-cell lymphoma treated with rituximab: a case report and review of literature
    Ajay Nooka
    Winship Cancer Institute Hematology and Medical Oncology, Emory University School of Medicine, Atlanta, GA, USA
    Clin Lymphoma Myeloma Leuk 11:379-84. 2011
    ....
  63. ncbi A randomized, placebo-controlled trial of subcutaneous administration of GM-CSF as a vaccine adjuvant: effect on cellular and humoral immune responses
    Jyoti Somani
    Department of Medicine, Winship Cancer Institute, Emory University School of Medicine, Atlanta, GA 30322, USA
    Vaccine 21:221-30. 2002
    ..Recipients of GM-CSF did not develop significantly higher numbers of TT responsive T-cells after vaccination compared to recipients who received placebo...
  64. ncbi Immunomodulatory effects of human recombinant granulocyte-macrophage colony-stimulating factor (rhuGM-CSF): evidence of antitumour activity
    Jason J Everly
    Winship Cancer Institute, Emory University School of Medicine, 1365Clifton Rd, Building C, Room 4004, Atlanta, GA 30322, USA
    Expert Opin Biol Ther 5:293-311. 2005
    ..In addition, dendritic cell modulation with rhuGM-CSF in haematopoietic progenitor grafts and rhuGM-CSF-transduced tumour vaccines will be discussed...
  65. ncbi Supportive therapies in multiple myeloma
    Charise Gleason
    Department of Hematology and Medical Oncology, Winship Cancer Institute, Emory University School of Medicine, Atlanta, Georgia 30322, USA
    J Natl Compr Canc Netw 7:971-9. 2009
    ....
  66. ncbi Novel treatment approaches for patients with relapsed and refractory multiple myeloma
    Rajni Sinha
    Winship Cancer Institute, Emory University, 1365 Clifton Road, Building C, Room 4004, Atlanta, GA 30322, USA
    Curr Treat Options Oncol 7:246-57. 2006
    ..The rapid clinical development of targeting agents will give us more options to treat patients with relapsed or refractory myeloma, thereby improving quality of life and overall survival...
  67. ncbi 14-3-3 Integrates prosurvival signals mediated by the AKT and MAPK pathways in ZNF198-FGFR1-transformed hematopoietic cells
    Shaozhong Dong
    Winship Cancer Institute, Emory University School of Medicine, Atlanta, GA 30322, USA
    Blood 110:360-9. 2007
    ..Our findings suggest that 14-3-3 integrates prosurvival signals in FGFR1 fusion-transformed hematopoietic cells. Disrupting 14-3-3-ligand association may represent an effective therapeutic strategy to treat 8p11 stem cell MPD...
  68. ncbi Development of drug-resistant herpes simplex virus infection after haploidentical hematopoietic progenitor cell transplantation
    Amelia A Langston
    Department of Hematology Oncology, Winship Cancer Institute, Emory University School of Medicine, Atlanta, GA 30302, USA
    Blood 99:1085-8. 2002
    ..The prolonged immunodeficiency associated with stringent lymphocyte depletion of the graft appears to strongly predispose to emergence of drug-resistant HSV. Furthermore, immune reconstitution is necessary for eradication of infection...
  69. ncbi PI3 kinase/AKT pathway as a therapeutic target in multiple myeloma
    R Donald Harvey
    Emory University School of Medicine, Winship Cancer Institute, 1365 C Clifton Road, Atlanta, GA 30322, USA
    Future Oncol 3:639-47. 2007
    ..Drugs such as perifosine that are specific for Akt are also in development. Combinations of these agents with existing therapies are rational approaches on the path to improving myeloma treatment...
  70. ncbi Management of toxicities associated with bortezomib
    Sagar Lonial
    Translational Research B-cell Malignancy Program, Winship Cancer Institute, Emory University, Atlanta, Georgia, USA
    Oncology (Williston Park) 20:1592-3, 1597. 2006
  71. ncbi Racial differences in the incidence and outcomes for patients with hematological malignancies
    Christopher R Flowers
    Winship Cancer Institute, Emory University School of Medicine, Atlanta, Georgia, USA
    Curr Probl Cancer 31:182-201. 2007
  72. ncbi Review of peripheral neuropathy in plasma cell disorders
    Jeannine Silberman
    Winship Cancer Institute, Emory University School of Medicine, Atlanta, GA 30322, USA
    Hematol Oncol 26:55-65. 2008
    ....
  73. ncbi Targeted therapy for haematological malignancies: clinical update from the American Society of Hematology, 2004
    Maureen Haas
    Winship Cancer Institute, Emory University School of Medicine, Atlanta, GA, USA
    Expert Opin Investig Drugs 14:1161-9. 2005
    ....
  74. ncbi Activity and safety of bortezomib in multiple myeloma patients with advanced renal failure: a multicenter retrospective study
    Asher A Chanan-Khan
    Roswell Park Cancer Institute, Elm and Carlton Sts, Buffalo, NY 14263, USA
    Blood 109:2604-6. 2007
    ..Further studies will more formally evaluate the impact of bortezomib-based regimens in this patient population...
  75. ncbi Multicenter phase II study of bortezomib in patients with relapsed or refractory mantle cell lymphoma
    Richard I Fisher
    University of Rochester, James P Wilmot Cancer Center, Rochester, USA
    J Clin Oncol 24:4867-74. 2006
    ..Evaluate response rate, duration of response (DOR), time-to-progression (TTP), overall survival (OS), and safety of bortezomib treatment in patients with relapsed or refractory mantle cell lymphoma (MCL)...
  76. ncbi A practical update on the use of bortezomib in the management of multiple myeloma
    Jesus San Miguel
    Hematology Department, Hospital Clinico Universitario de Salamanca, Servicio de Hematologia, Paseo de San Vicente 58, Salamanca E 37007, Spain
    Oncologist 11:51-61. 2006
    ..Information is given on the practical management of the most common adverse events, including peripheral neuropathy and thrombocytopenia, and the use of bortezomib in renal and hepatic impairment...
  77. ncbi Bortezomib or high-dose dexamethasone for relapsed multiple myeloma
    Paul G Richardson
    Dana Farber Cancer Institute, Boston, MA 02115, USA
    N Engl J Med 352:2487-98. 2005
    ..This study compared bortezomib with high-dose dexamethasone in patients with relapsed multiple myeloma who had received one to three previous therapies...
  78. ncbi Designing risk-adapted therapy for multiple myeloma: the Mayo perspective
    Sagar Lonial
    Mayo Clin Proc 82:279-81. 2007
  79. ncbi Safety and efficacy of bortezomib in high-risk and elderly patients with relapsed multiple myeloma
    Paul G Richardson
    Medical Oncology, Dana Farber Cancer Institute, 44 Binney Street, Boston, MA 02115, USA
    Br J Haematol 137:429-35. 2007
    ..Bortezomib should be considered an appropriate treatment for elderly and high-risk patients with relapsed multiple myeloma...
  80. ncbi Extended follow-up of a phase 3 trial in relapsed multiple myeloma: final time-to-event results of the APEX trial
    Paul G Richardson
    Dana Farber Cancer Institute, Boston, MA 02115, USA
    Blood 110:3557-60. 2007
    ..These data confirm the activity of bortezomib and support extended treatment in relapsed multiple myeloma patients tolerating therapy...
  81. ncbi A practical guide to achieving and maintaining the best response to lenalidomide in multiple myeloma: roundtable proceedings
    Edward A Stadtmauer
    Hematology/Oncology Division, University of Pennsylvania Health System, Abramson Cancer Center, University of Pennsylvania School of Medicine, Philadelphia, PA 19104, USA
    Clin Adv Hematol Oncol 5:7-19, quiz 21-2. 2007
  82. ncbi Lenalidomide plus dexamethasone for relapsed multiple myeloma in North America
    Donna M Weber
    Department of Lymphoma and Myeloma, M D Anderson Cancer Center, Houston, TX 77030, USA
    N Engl J Med 357:2133-42. 2007
    ..Lenalidomide, an oral immunomodulatory drug that is similar to thalidomide but has a different safety profile, has clinical activity in relapsed or refractory multiple myeloma...
  83. ncbi Analysis of herpes zoster events among bortezomib-treated patients in the phase III APEX study
    Asher Chanan-Khan
    Roswell Park Cancer Institute, Elm and Carlton Streets, Buffalo, NY 14263, USA
    J Clin Oncol 26:4784-90. 2008
    ..The aim of this subset analysis was to determine if bortezomib treatment is associated with increased incidence of varicella-zoster virus (VZV) reactivation in patients with relapsed multiple myeloma (MM)...
  84. ncbi Eliminating the complete response penalty from myeloma response assessment
    Sagar Lonial
    Blood 111:3297-8. 2008